Literature DB >> 788751

Pharmacokinetics of indoramin in man.

G H Draffan, P J Lewis, J L Firmin, T W Jordan, C T Dollery.   

Abstract

1 The fate of oral and intravenous indoramin has been studied after single doses in man using the 14C labelled drug. Plasma concentrations of indoramin have been determined during chronic oral antihypertensive therapy employing a stable isotope dilution assay. 2 Following singleoral dosing the drug is well absorbed and extensively metabolised. Faecal excretion in 72 h accounts for 46% of the administered radioactivity of which approximately 4% is associated with indoramin. Less than 2% of the radioactivity in urine is accountable as the concentration of total metabolites. Peak plasma levels both of drug and metabolites occur 1-2 h after dosing, the maximal lowering of blood pressure occurring at this time. 3 The clearance of indoramin, determined after intravenous administration is of the same order as liver blood flow. In the isolated perfused rat liver, the extraction ratio is 0.98.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 788751      PMCID: PMC2958773          DOI: 10.1111/j.1365-2125.1976.tb00626.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

1.  Clinical evaluation of indoramin, a new antihypertensive agent.

Authors:  P J Lewis; C F George; C T Dollery
Journal:  Eur J Clin Pharmacol       Date:  1973-12       Impact factor: 2.953

2.  Cardiovascular actions of Wy 21901, a new hypotensive and anti-arrhythmic agent.

Authors:  B J Alps; E S Johnson; A B Wilson
Journal:  Br J Pharmacol       Date:  1970-09       Impact factor: 8.739

3.  Treatment of essential hypertension with combined vasodilation and beta-adrenergic blockade.

Authors:  R Zacest; E Gilmore; J Koch-Weser
Journal:  N Engl J Med       Date:  1972-03-23       Impact factor: 91.245

4.  Pharmacologic studies of indoramin in man.

Authors:  R B Royds; D J Coltart; J D Lockhart
Journal:  Clin Pharmacol Ther       Date:  1972 May-Jun       Impact factor: 6.875

5.  The dependence of paracetamol absorption on the rate of gastric emptying.

Authors:  R C Heading; J Nimmo; L F Prescott; P Tothill
Journal:  Br J Pharmacol       Date:  1973-02       Impact factor: 8.739

6.  Plasma propranolol levels in adults with observations in four children.

Authors:  D G Shand; E M Nuckolls; J A Oates
Journal:  Clin Pharmacol Ther       Date:  1970 Jan-Feb       Impact factor: 6.875

7.  "First-pass" metabolism of paracetamol in rat liver.

Authors:  G M Cohen; O M Bakke; D S Davies
Journal:  J Pharm Pharmacol       Date:  1974-05       Impact factor: 3.765

8.  Gluconeogenesis in the perfused rat liver.

Authors:  R Hems; B D Ross; M N Berry; H A Krebs
Journal:  Biochem J       Date:  1966-11       Impact factor: 3.857

  8 in total
  13 in total

1.  The authors reply.

Authors:  P Collins; D Sheridan
Journal:  Br Heart J       Date:  1986-02

2.  Pharmacokinetics and systemic availability of the antihypertensive agent indoramin and its metabolite 6-hydroxyindoramin in healthy subjects.

Authors:  D M Pierce; S M Abrams; R A Franklin
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

3.  Intra- and inter-subject variation in the pharmacokinetics of indoramin and its 6-hydroxylated metabolite.

Authors:  D M Pierce; S M Abrams; R A Franklin
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  Pharmacokinetics of intravenous indoramin in middle-aged male and female volunteers.

Authors:  H M Norbury; R A Franklin; P K Marrott; S J Warrington
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Death due to overdose of indoramin.

Authors:  R Hunter
Journal:  Br Med J (Clin Res Ed)       Date:  1982-10-09

6.  Death due to overdose of indoramin.

Authors:  P K Marrott; J F Waterfall
Journal:  Br Med J (Clin Res Ed)       Date:  1982-12-04

7.  Effect of indoramin on finger blood flow in vasospastic patients.

Authors:  D L Clement
Journal:  Eur J Clin Pharmacol       Date:  1978-12-18       Impact factor: 2.953

Review 8.  Indoramin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and related vascular, cardiovascular and airway diseases.

Authors:  B Holmes; E M Sorkin
Journal:  Drugs       Date:  1986-06       Impact factor: 9.546

9.  Studies on the metabolism of the new anti-hypertensive agent, indoramin, in man.

Authors:  R A Franklin; P Robson; D Stevenson
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 10.  Metabolites of antihypertensive drugs. An updated review of their clinical pharmacokinetic and therapeutic implications.

Authors:  A Ebihara; A Fujimura
Journal:  Clin Pharmacokinet       Date:  1991-11       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.